IGC Pharma Stock Price, News & Analysis (NYSEAMERICAN:IGC) $0.30 0.00 (0.00%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$0.30▼$0.3150-Day Range N/A52-Week Range$0.27▼$0.49Volume76,622 shsAverage Volume173,770 shsMarket Capitalization$19.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort Interest About IGC Pharma Stock (NYSEAMERICAN:IGC)IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Read More IGC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IGC Stock News HeadlinesDecember 6, 2023 | finance.yahoo.comIGC Pharma Announces Collaboration to Integrate AI into Clinical TrialsDecember 6, 2023 | americanbankingnews.comIGC Pharma (NYSEAMERICAN:IGC) Share Price Crosses Above 200 Day Moving Average of $0.00December 8, 2023 | Financial Alphas (Ad)Recent Reports Are A Wake-Up Call For InvestorsAs the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.November 24, 2023 | money.usnews.comIGC Pharma IncNovember 22, 2023 | msn.comAI And THC: IGC Pharma Teams Up With Colombian University For Alzheimer's Treatment ResearchNovember 21, 2023 | finance.yahoo.comIGC Pharma Announces Master Agreement with Leading South American University to Advance AI InitiativesNovember 13, 2023 | finance.yahoo.comIGC Pharma Reports Second Quarter Fiscal 2024 ResultsOctober 19, 2023 | finance.yahoo.comIGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief TherapyDecember 8, 2023 | Financial Alphas (Ad)Recent Reports Are A Wake-Up Call For InvestorsAs the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.September 8, 2023 | finance.yahoo.comIGC Pharma, Inc. (IGC)August 21, 2023 | finance.yahoo.comIGC Announces Results of its 2023 Annual Stockholders MeetingAugust 14, 2023 | finance.yahoo.comIGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical TrialsAugust 9, 2023 | msn.comIGC powers Alzheimer’s and cannabis research with AIAugust 3, 2023 | benzinga.comTHC-Based Alzheimer's Trial In Puerto Rico: IGC Pharma Targets Underrepresented Hispanic CommunitiesAugust 2, 2023 | finance.yahoo.comIGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto RicoJuly 18, 2023 | finance.yahoo.comIGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International ConferenceJuly 12, 2023 | msn.comIGC Pharma FY23 Revenue Grows 129%, What About Net Loss?July 12, 2023 | finance.yahoo.comIGC Reports Financial Results for Fiscal Year Ended March 31, 2023July 7, 2023 | benzinga.comIGC Pharma Secures $12M Credit Facility From O-Bank To Aid Alzheimer's ResearchJuly 6, 2023 | msn.comIGC Pharma Secures $3M Via Private PlacementJuly 6, 2023 | msn.comIGC Raises $3M Via Private Placement With Asset Management Firm BradburyJuly 6, 2023 | finance.yahoo.comIGC Pharma Announces a $3 Million Private Placement of its Common StockJune 16, 2023 | fool.comIndia Globalization Capital (NYSEMKT: IGC)June 6, 2023 | finance.yahoo.comIGC Pharma Receives Notice of Allowance for Patent on SeizuresJune 5, 2023 | finance.yahoo.comIGC Pharma’s Advisor and Inventor of Drug Candidate TGR-63 Receives AwardMay 18, 2023 | finance.yahoo.comIGC Pharma to Present at LD Micro Invitational XIIIMay 8, 2023 | marketwatch.com8-K: IGC Pharma, Inc.See More Headlines Receive IGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/08/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:IGC CUSIPN/A CIK1326205 Webwww.igcinc.us Phone(301) 983-0998Fax240-465-0273Employees61Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,510,000.00 Net Margins-803.94% Pretax Margin-803.94% Return on Equity-71.40% Return on Assets-62.25% Debt Debt-to-Equity Ratio0.01 Current Ratio2.90 Quick Ratio1.65 Sales & Book Value Annual Sales$910,000.00 Price / Sales21.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book1.07Miscellaneous Outstanding Shares63,730,000Free Float51,625,000Market Cap$19.12 million OptionableNot Optionable Beta1.69 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Ram Mukunda (Age 64)President, CEO & Director Comp: $705kMs. Claudia Grimaldi (Age 52)VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director Comp: $245kMr. Rohit Goel (Age 29)Senior Director of Accounting & Principal Accounting Officer Key CompetitorsCalciMedicaNASDAQ:CALCPieris PharmaceuticalsNASDAQ:PIRSMainz BiomedNASDAQ:MYNZNeuroBo PharmaceuticalsNASDAQ:NRBOViracta TherapeuticsNASDAQ:VIRXView All CompetitorsInstitutional OwnershipCommonwealth Equity Services LLCBought 112,334 shares on 10/23/2023Ownership: 0.308%View All Institutional Transactions IGC Stock Analysis - Frequently Asked Questions How have IGC shares performed in 2023? IGC Pharma's stock was trading at $0.40 at the beginning of 2023. Since then, IGC stock has decreased by 24.3% and is now trading at $0.3027. View the best growth stocks for 2023 here. Are investors shorting IGC Pharma? IGC Pharma saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 970,000 shares, an increase of 16.2% from the October 15th total of 835,000 shares. Based on an average daily volume of 248,200 shares, the days-to-cover ratio is currently 3.9 days. View IGC Pharma's Short Interest. How were IGC Pharma's earnings last quarter? IGC Pharma, Inc. (NYSEAMERICAN:IGC) issued its quarterly earnings data on Thursday, November, 9th. The construction company reported ($0.05) earnings per share for the quarter. The construction company earned $0.29 million during the quarter. IGC Pharma had a negative trailing twelve-month return on equity of 71.40% and a negative net margin of 803.94%. What other stocks do shareholders of IGC Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other IGC Pharma investors own include GW Pharmaceuticals (GWPH), Alibaba Group (BABA), Tilray (TLRY), Cronos Group (CRON), Micron Technology (MU), NewAge (NBEV), Advanced Micro Devices (AMD), Ford Motor (F) and NIO (NIO). Who are IGC Pharma's major shareholders? IGC Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Commonwealth Equity Services LLC (0.31%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ram Mukunda and Richard K Prins. View institutional ownership trends. How do I buy shares of IGC Pharma? Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSEAMERICAN:IGC) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGC Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.